Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
09/22 Hang Lung Properties to Bring in Conrad Hotel Project
09/16 ASTELLAS PHARMA : Selected as a Dow Jones Sustainability Asia Pacific Index Comp..
09/15 ASTELLAS PHARMA : and MPM debut DigiTx Partners, a digital health investment com..
09/09 ASTELLAS PHARMA : Findings from Astellas Pharma, Inc. in the Area of Nuclear Mag..
09/09 ASTELLAS PHARMA : Study Results from Astellas Pharma, Inc. Provide New Insights ..
09/08 ASTELLAS PHARMA : donates ambulances on First Aid Day (September 9)
08/25 ASTELLAS PHARMA : and World Transplant Games Federation Announce Launch of Fit f..
08/24 ASTELLAS PHARMA : Announces Personnel Changes
08/23 ASTELLAS PHARMA : Announces Personnel Changes (pdf 47KB)
08/22 ASTELLAS PHARMA : and World Transplant Games Federation Announce Launch of Fit f..
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/19 Vical's CMV vaccine candidate flunks mid-stage study; shares off 22% premarke..
09/08 Cytokinetics initiates IND-enabling studies for next-gen skeletal muscle acti..
08/24 PFIZER-MEDIVATION DEAL : Good Or Bad For Shareholders?
08/23 Who's Next After Medivation?
08/22 Pfizer Pays Up
Advertisement
Financials ( JPY)
Sales 2017 1 334 868 M
EBIT 2017 280 000 M
Net income 2017 198 585 M
Finance 2017 469 745 M
Yield 2017 2,16%
P/E ratio 2017 16,91
P/E ratio 2018 15,68
EV / Sales 2017 2,22x
EV / Sales 2018 2,06x
Capitalization 3 434 271 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 1 967  JPY
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Masafumi Nogimori Chairman
Yasumasa Masuda Senior Executive Officer & Head-Finance
Mitsunori Matsuda Senior Executive Officer & GM-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-7.19%33 972
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results